Paper5331901
The antitumor activity of Escherichia coli L-asparaginase.
Roberts J and 2 others. Cancer Res, 1966. Cited by 118 papers, by iCite.
Cite this record
ConductScience Library. The antitumor activity of Escherichia coli L-asparaginase. Papers, record 5331901. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/5331901
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Amidohydrolases | Major topic |
| Antineoplastic Agents | Major topic |
| Escherichia coli | Major topic |
| Neoplasms, Experimental | Major topic |
| Animals | |
| Mice |
Source PubMed
Cited by27
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 118 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40237204 | Biochemical and Biophysical Divergences between Two Escherichia coli l-Asparaginase II Variants: Potential for Using EcA2-K12 as a Biosimilar. | Biochemistry | 2025 | https://conductscience.org/library/papers/40237204 | PubMed |
| 40195325 | L-asparaginase is a PAR2 N-terminal protease that unmasks the PAR2 tethered ligand. | Cell Death Discov | 2025 | https://conductscience.org/library/papers/40195325 | PubMed |
| 39065214 | Extracellular Membrane Vesicles of Escherichia coli Induce Apoptosis of CT26 Colon Carcinoma Cells. | Microorganisms | 2024 | https://conductscience.org/library/papers/39065214 | PubMed |
| 38792133 | Substrate Affinity Is Not Crucial for Therapeutic L-Asparaginases: Antileukemic Activity of Novel Bacterial Enzymes. | Molecules | 2024 | https://conductscience.org/library/papers/38792133 | PubMed |
| 36828987 | Biochemical characterization of extremozyme L-asparaginase from Pseudomonas sp. PCH199 for therapeutics. | AMB Express | 2023 | https://conductscience.org/library/papers/36828987 | PubMed |
| 36310372 | The E. coli L-asparaginase V27T mutant: structural and functional characterization and comparison with theoretical predictions. | FEBS Lett | 2022 | https://conductscience.org/library/papers/36310372 | PubMed |
| 36152020 | The dimeric form of bacterial l-asparaginase YpAI is fully active. | FEBS J | 2023 | https://conductscience.org/library/papers/36152020 | PubMed |
| 32297090 | Production, characterization and bioinformatics analysis of L-asparaginase from a new Stenotrophomonas maltophilia EMCC2297 soil isolate. | AMB Express | 2020 | https://conductscience.org/library/papers/32297090 | PubMed |
| 31387272 | Microalgal Enzymes with Biotechnological Applications. | Mar Drugs | 2019 | https://conductscience.org/library/papers/31387272 | PubMed |
| 30900037 | Experimental and bioinformatics study for production of L-asparaginase from Bacillus licheniformis: a promising enzyme for medical application. | AMB Express | 2019 | https://conductscience.org/library/papers/30900037 | PubMed |
| 25573198 | Effect of premedications in a murine model of asparaginase hypersensitivity. | J Pharmacol Exp Ther | 2015 | https://conductscience.org/library/papers/25573198 | PubMed |
| 22895060 | Rhizobium etli asparaginase II: an alternative for acute lymphoblastic leukemia (ALL) treatment. | Bioengineered | 2013 | https://conductscience.org/library/papers/22895060 | PubMed |
| 22042277 | Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866). | J Pediatr Hematol Oncol | 2011 | https://conductscience.org/library/papers/22042277 | PubMed |
| 18046445 | Fresh frozen plasma contains free asparagine and may replace the plasma asparagine pool during L-asparaginase therapy. | Leukemia | 2008 | https://conductscience.org/library/papers/18046445 | PubMed |
| 8004756 | Liposomal palmitoyl-L-asparaginase: characterization and biological activity. | Cancer Chemother Pharmacol | 1994 | https://conductscience.org/library/papers/8004756 | PubMed |
| 5000866 | L-Asparaginase from Proteus vulgaris. | Appl Microbiol | 1971 | https://conductscience.org/library/papers/5000866 | PubMed |
| 4995652 | Purification and properties of L-asparaginase from Serratia marcescens. | J Bacteriol | 1971 | https://conductscience.org/library/papers/4995652 | PubMed |
| 4970225 | New procedures for purification of L-asparaginase with high yield from Escherichia coli. | J Bacteriol | 1968 | https://conductscience.org/library/papers/4970225 | PubMed |
| 4904782 | [Inhibition of malignant human neoplasms with L-asparaginase]. | Klin Wochenschr | 1969 | https://conductscience.org/library/papers/4904782 | PubMed |
| 4904781 | [L-asparaginase and leukemia]. | Klin Wochenschr | 1969 | https://conductscience.org/library/papers/4904781 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/5331901
GET https://conductscience.org/api/papers/v1/5331901/cited_by?page=2